Palvella Therapeutics, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

PTX-022 · Oncology
PTX-022 is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) designed to modulate immune cell function and tumor microenvironment.
QTORIN 3.9% rapamycin anhydrous gel · Dermatology
QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Palvella Therapeutics, Inc. portfolio CI brief
Palvella Therapeutics, Inc. pipeline updates RSS